Compare Equinor ASA (EQNR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs TG Therapeutics Inc — how do they compare? Equinor ASA trades at $43.02 (market cap $101.62B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: Equinor ASA is far larger — about 12.5× TG Therapeutics Inc's market cap, and Equinor ASA pays a 3.63% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and TG Therapeutics Inc for 16 Days on average.
| EQNR | TGTX | |
|---|---|---|
Market Cap | $101.62B | $8.16B |
Volume | 4,991,782 | 1,735,121 |
Sector | Energy | Health |
52-Week High | $45.75 | $59.06 |
52-Week Low | $22.41 | $26.94 |
Typical Hold Time | 59 Days | 16 Days |
Enterprise Value | $110.31B | $8.37B |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $43.01, up 3.36% today, with strong technical momentum indicated by bullish moving averages. The stock shows attractive valuation metrics with a P/E of 11.63 and EV/EBITDA of 2.39, while recent earnings beat expectations in two of the last three quarters. The company maintains solid profitability with 21.32% ROE and continues strategic expansion in LNG markets through new supply agreements.
EQNR presents compelling value with significant upside to the $87.50 consensus price target, though investors face risks from volatile energy prices and declining profit margins. The company's LNG expansion strategy and share buyback program provide catalysts, but execution risks and commodity price sensitivity require careful monitoring.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
